The article you requested is
Drs. Findling and Colleagues Reply
J Clin Psychiatry 1997;58:178-179 [letter]
Copyright 1997 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $40
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP print + online for $166 individual.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Letter to the Editor
Sir: We appreciate the interest Dr. Smith has taken in our
work which examined venlafaxine in adults with attention-
deficit/hyperactivity disorder (ADHD). However, our rationale
for initiating a clinical trial with venlafaxine in adults
with this syndrome was not simply due to the fact that venlafaxine
is an antidepressant. The reason we initiated a trial with
venlafaxine was that the effect of venlafaxine on both serotonergic
and noradrenergic neural transmission is a pharmacologic
profile shared with the tricyclic antidepressants.